Tandem high-dose therapy followed by autologous stem-cell transplantation for refractory or relapsed high grade non-hodgkin's lymphoma with poor prognosis factors: A prospective pilot study

Haematologica

Volumn 87, Issue 3, 2002, Pages 333-334

  Le Gouill, Steven ^a   Moreau, Philippe ^a   Morineau, Nadine ^a   Harousseau, Jean Luc ^a   Milpied, Noël ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

High grade lymphoma; Relapse; Tandem autologous stem cell transplantation; Transformation of low grade lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; DRUG MEGADOSE; FEMALE; HUMAN; LYMPHOMA; MALE; NONHODGKIN LYMPHOMA; PILOT STUDY; PROGNOSIS; PROSPECTIVE STUDY; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0036197549     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial
2. Effective salvage therapy for lymphoma with cisplatin in combination with high dose AraC and dexamethasone (DHAP)
3. Combination of etoposide, high-dose AraC and solumedrol with or without platinum in relapsing or recurrent lymphoma
4. Idarubicin and high dose cytarabine: A new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma
5. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation
6. Report of an international workshop to standardize response criteria for non Hodgkin's lymphomas
7. High survival rate of childhood B-cell lymphoma and leukemia (ALL) as result of the LMB 89 protocol of the SFOP
8. Results of MIME salvage regimen for recurrent or refractory lymphoma
9. Intensive chemotherapy with high doses of BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) followed by autologous bone marrow transplantation. Toxicity and antitumor activity in 26 patients with poor risk malignancies
10. Escalading dose of mitoxantrone with high-dose cyclophosphamide, carmustine and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation